One hundred and eighteen doctors who treat pulmonary neoplasms in Ontario were asked how they would wish to be treated if they had non-small cell lung cancer. Four different scenarios were given. The physicians were then asked if they would consent to take part as subjects in one or more clinical trials for which they would be eligible in those situations. The proportion of respondents who would consent to each study ranged from 11% to 64%. Reasons given for refusing to participate as subjects in each trial were varied, but many felt that the trials offered unacceptable options for treatment. Medical oncologists consented to each study more frequently than radiation oncologists, respirologists or thoracic surgeons but all disciplines ranked the 6 studies in the same order of acceptability. It is concluded that some patients with non-oat cell lung cancer currently receive experimental therapies with high risk/benefits ratios which experts in the field would not accept for themselves. It is suggested that the expert surrogate system may be useful as an adjunct to the institutional review board in evaluating new trials before they are activated.
The Nuremberg code (1949) states that the voluntary consent of the subject is absolutely essential in human experimentation and the Declaration of Helsinki in addition demands that 'the potential subject must be adequately informed of the aims, anticipated benefits and potential hazards of the study and the discomfort it may entail' (World Medical Association, 1964) . Hence 'informed consent' has become widely accepted as essential in clinical trials but it has proved difficult to define and, once defined, difficult to achieve in practice. Numerous empirical studies have shown that many patients who have given their 'informed consent' have little idea of what they have consented to (Epstein et al., 1969; Robinson et al., 1976; Schultz et al., 1976; Muss et al., 1979) , and that trust in the doctor and fear of the illness remain primary reasons for participating in clinical trials (Penman et al., 1984; Saurbrey et al., 1984) . Fost (1975) suggested that one of the major barriers to communication is the emotional state of the patient which, in the context of a serious illness, may preclude rational consideration of any proposed study. He has therefore argued for the use of lay surrogates to evaluate clinical trials. The essence of this process is to obtain a response from individuals who are not candidates for investigations or therapeutic procedures but who are asked to behave as if they were (Fost, 1975 clearer mind than the patient and his decision will not be influenced by his dependence on the doctor.
The emotional state of the patient is not the only limitation to the validity of informed consent. Ingelfinger (1972) said that the trouble with informed consent is that it is not educated consent, and Jonas (1969) argued that ultimately the researcher himself makes the ideal research subject since it is he who best understands the issues at stake and the risks involved. We Each individual was sent a written questionnaire which had 4 components: (a) the physicians were asked for demographic information and details of their education and current practice; (b) the subjects were asked how they personally would wish to be managed if they had lung cancer (four specific scenarios were given with open ended questions); (c) the subjects were then asked if they would consent to be treated on 6 randomized trials for which they would be eligible in those situations. The investigators' summary of each study as supplied to the International Cancer Research Data Bank accompanied the questionnaire as an appendix but was also summarized in the main body of the form (these questions required yes/no answers); (d) if the subject would not consent he or she was asked to identify the arms of the study which were unacceptable and to explain why.* Seventy-nine completed questionnaires were returned. Results were analyzed using the SSPS-X program (SSPS Inc.) Seventy-eight subjects answered the question and 52.6% said that they would consent. Table I shows that more medical oncologists than radiation oncologists consented to this study and doctors who spent more than 10% of their time on research consented more frequently than those who spent less time on research. All 79 answered this question of whom only 9 (11.4%) said that they would consent. This study was uniformly rejected by all groups regardless of background and experience (Table I) . Sixty-four of the 70 who refused to participate rejected both Arm 1 and Arm 2. The same reasons were given for rejecting each arm: toxicity of chemotherapy was mentioned by 75%, ineffectiveness of chemotherapy was mentioned by 57.8% and 6% indicated that they wished to have radiotherapy instead. Seventy-eight of 79 respondents answered this question of whom 50 (64.1%) said that they would consent. Medical oncologists consented more frequently than radiation oncologists and there was also a significant inverse correlation between acceptability of the study and the number of new cases of lung cancer which the respondent treated each year (Table I) . Twenty-six subjects rejected Arm 2 only and all of these expressed concern that lesser surgery might be inadequate. Two subjects rejected both Arm 1 and Arm 2 because they wished adjuvant treatment.
Study IV was a randomized study of intratumoral BCG prior to surgery for non-small cell carcinoma of the lung from Yale University Reasons given for rejecting all arms of the study include the toxicity of chemotherapy (60%), the ineffectiveness of chemotherapy (70%), and the lack of radiotherapy (17%). The study was uniformly unpopular regardless of the background and experience of the subjects (Table  I) .
Factors affecting consent
We have attempted to look for factors influencing general attitudes to clinical trials by scoring the total number of trials to which each respondent would consent and these data are shown in Figure  1 . Neither age nor sex had any influence on attitudes (Figure 1, panel B, C, D and E) . Panels N and 0 of Figure 1 show that 65% of radiation oncologists refused all, or all but one of the 6 studies compared to only 14.2% of medical oncologists (P<0.001). Those who did not actually treat lung cancer on clinical trials did not differ from those who did (Figure 1 , panels I and J), but there was a significant correlation between time spent on research and likelihood of giving consent (Figure 1 , panels K, L and M). The effect of the number of new cases of lung cancer seen by the respondent each year was curious (Figure 1 , panels F, G and H). Fifty-four percent of those who treated more than 50 new lung cancer patients each year rejected all or all but one of the 6 studies, compared to 35% of those who treated fewer new cases (P<0.01) but 16.7% of this same high case load group were at the opposite extreme and consenting to all or all but one of the studies, compared to only 1.8% of those who saw fewer cases of lung cancer (P<0.05). Smokers showed no overall difference in attitude to the 6 trials compared to non-smokers. Our reason for studying the influence of smoking history was that for smokers these questions, though hypothetical, were very real ones which we believed they might have asked themselves previously. In their evaluation of these clinical trials the smokers do appear to be more discriminating than the rest, in that those studies which were popular overall were even more Number of studies accepted Figure 1 The number of studies which are accepted by each subgroup of doctors in the form of a frequency distribution.
acceptable to the smokers and those which were generally unpopular were even less acceptable to the smokers (see Table I ) III, 64.1% consent) and the least popular (Study II, 11.4% consent) was statistically highly significant (P<0.00001). There are also statistically significant differences between either of the 2 studies accepted by the majority and any of the 4 studies rejected by the majority (P<0.005 in every case). Surrogate refusal to participate in a trial might merely indicate the existence of prejudices which the study was designed to overcome but our data suggest that this is not the case: if the subjects irrationally rejected clinical trials because of unfounded personal preferences, some subjects should reject one arm while other subjects should reject the other. In contrast, in any of the 4 trials which were rejected by the majority, either one arm was singled out for rejection (as in Study IV) or all arms were rejected (as in Study II). Furthermore, while medical oncologists were in any given situation more likely to consent than radiation oncologists, we find that both groups of doctors rank the studies in the same order of acceptability (see Table I ). Likewise, those doctors who do research were more likely overall to consent than those who are not active in research (Figure 1 ) but both groups were in complete agreement about the order of acceptability of the 6 trials (see Table I ).
Thus the differences between the studies cannot be explained as merely reflecting bias engendered by background and training.
Reasons given by surrogates for their refusal to participate may be important also in assessing the more frequently accepted studies. In Situation B we found no evidence of any controversy in the choices of management of our respondents, but 64. 1% consented to participate in Study III, a comparison of standard therapy by lobectomy with lesser surgery. Thus Study III seems even more acceptable than Study I but an examination of the reasons given for refusal reveals important differences between these two studies. Those who rejected Study I did so for diverse reasons but those who rejected Study III rejected one particular arm and did so for a single cogent reason. Furthermore, the study was least acceptable to those doctors with the greatest experience in the management of lung cancer.
The Ontario clinics are non-surgical oncology centers so that thoracic surgeons were underrepresented on our list of doctors who treat lung cancer in Ontario. The exhaustive nature of the sample and the high response rate (67%), however, provide us with some assurance that the views of medical and radiation oncologists in the province have been fairly represented. We have no reason to doubt that this reflects opinion in the rest of Canada, but we cannot extrapolate beyond our own borders. It is, however, interesting that British trained doctors in this study did not differ in their views from their North American trained colleagues. We do not, of course, know if doctors in other specialities or in general practice would give the same sort of answers but the very similar views expressed here by the different disciplines makes it unlikely that there would be major variations in opinion across the profession.
The clinical trials which our surrogates evaluated were chosen by us to exemplify different types of study which were then in progress in non-small cell lung cancer. They were not picked randomly and may not be representative in content or quality of the ongoing work in the field. Nonetheless, the finding that most specialists who treat lung cancer would not consent to participate as subjects in many of these trials is of concern. If experts refuse to participate in a trial, should uncomprehending patients be asked to consent? It is likely that opinions will vary on this point so we have resubmitted our results to the original respondents to obtain their views, and to find out if there is any consensus as to how to act on this type of information. If the method proves to have general credibility, expert surrogates may be a useful adjunct to institutional review boards or ethics committees in evaluating the acceptability of new protocols. The growing pressure on doctors to carry out clinical trials and publish their results makes it essential to take every possible step to protect the patient's interests. It can be argued that sufficient safeguards already exist but we believe that there have been insufficient empirical studies of the clinical trials process to be sure of this (Mackillop & Johnston, 1985) .
